Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - benralizumabum - lnjektionslösung - benralizumabum 30 mg, histidinum, histidini hydrochloridum monohydricum, trehalosum dihydricum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - schweres eosinophiles asma - biotechnologika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - exenatidum - depot-lnjektionssuspension in einem autoinjektor - exenatidum 2 mg, saccharum, poly(lactidum-co-glycolidum) 50/50 (0.40 - 0.49 dl/g), triglycerida media, ad suspensionem pro dosi. - antidiabetico - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - acalabrutinibum - capsule rigide - acalabrutinibum 100 mg, cellulosum microcristallinum silicificatum, amylum pregelificatum, carboxymethylamylum natricum a corresp. natrium max. 0.25 mg, magnesii stearas, kapselhülle: gelatina, e 172 (flavum), e 132, e 171, drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammonii hydroxidum, pro capsula. - chronisch lymphatische leukämie (cll) - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - agenti antineoplastici - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - budesonidum, glycopyrronium, formoteroli fumaras dihydricus - druckgasinhalation, suspension - budesonidum 160 µg, glycopyrronii bromidum 9 µg corresp. glycopyrronium 7.2 µg, formoteroli fumaras dihydricus 5 µg, 1,2-distearoyl-sn-glycero-3-phosphocholinum, calcii chloridum dihydricum, norfluranum, ad suspensionem pro dosi. - bpco - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - tezepelumabum - soluzione iniettabile in siringa preriempita - tezepelumabum 210 mg, prolinum, acidum aceticum glaciale, polysorbatum 80, natrii hydroxidum q.s. ad ph, aqua ad iniectabile, ad solutionem pro 1.91 ml. - zusatztherapie bei schwerem asthma - biotechnologika

Unione Europea - italiano - EMA (European Medicines Agency)

astrazeneca ab - nirsevimab - sieri immuni e immunoglobuline, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.

Unione Europea - italiano - EMA (European Medicines Agency)

astrazeneca ab - olaparib - neoplasie ovariche - agenti antineoplastici - ovarico cancerlynparza è indicato come monoterapia per il trattamento di mantenimento di pazienti adulti con avanzate (figo stadi iii e iv) brca1/2-mutato (germinale e/o somatica) di alta qualità epiteliali dell'ovaio, tube di falloppio o del cancro peritoneale primario che si trovano in risposta (completa o parziale) a seguito del completamento della prima linea di chemioterapia a base di platino. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 e 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. i pazienti devono essere stati precedentemente trattati con un'antraciclina e un taxano il (neo)adiuvante o metastatico impostazione a meno che i pazienti non erano adatti per questi trattamenti (vedere la sezione 5. i pazienti con recettore ormonale (hr)-positivo il cancro al seno dovrebbero avere fatto passi avanti o dopo la prima terapia endocrina, o essere considerati non idonei per la terapia endocrina. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

astrazeneca spa - dopamina cloridrato - preparazione iniettabile - "200 mg/5 ml concentrato per soluzione per infusione" 10 fiale 5 ml

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

astrazeneca s.p.a. - tamoxifene - tamoxifene